uniQure N.V.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| QURE | MRVI | RARE | SLDB | DSGN | NGNE | |
|---|---|---|---|---|---|---|
| Market cap | 1.51B | 2.61B | 1.51B | 719.48M | 682.77M | 489.08M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -7.2 | -70.1 | 25.8 | -3.9 | -6.7 | -4.3 |
| Price/book | 4.7 | 5.1 | -5.2 | 1.9 | 3.4 | 1.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −63.58% | +125.45% | −51.66% | +14.31% | +64.80% | −16.51% |
| Today | −3.32% | −5.11% | −1.16% | −2.33% | −6.35% | −7.42% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All QURE news ›Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against uniQure N.V. (QURE) And Encourages Stockholders to Reach Out
ACCESS Newswire Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against uniQure N.V. (QURE) And Encourages Stockholders to Reach Out Thursday, 08 October 2026 01:00 PM On September 29, 2026, uniQure released…
Mixed results from Huntington's gene therapy trial after four years
A gene therapy for Huntington's disease failed to show statistically significant slowing of disease progression after 48 months, according to newly released data. Huntington's disease is a rare genetic condition caused by too many…
The Other Shoe Drops: uniQure Shares Plans To Submit Licensing Application With The FDA for AMT-130
After a turbulent past year, uniQure have shared encouraging news that the FDA has agreed their Phase I/II study data can serve as the basis for an application that could lead to the approval of AMT-130 in the US. Unlike many other…
uniQure (NASDAQ:QURE) and Vir Biotechnology (NASDAQ:VIR) Critical Review
Vir Biotechnology (NASDAQ:VIR – Get Free Report) and uniQure (NASDAQ:QURE – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their…
Wilson Disease Market Gains Momentum as a First-in-Class Therapy Heads Toward FDA Review and Gene Therapy Advances | Thelansis
Wilson Disease Market Gains Momentum as a First-in-Class openPR.com Wilson Disease Market Gains Momentum as a First-in-Class Therapy Heads Toward FDA Review and Gene Therapy Advances | Thelansis Press release from: THELANSIS KNOWLEDGE…
UNIQURE N.V. QURE INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 37.3% Share Drop
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of uniQure N.V. (“uniQure” or the “Company”) (NASDAQ: QURE) investors concerning the Company’s and/or members of its senior…
Transcripta Bio & Synfini Collaborate to Identify a Lead Candidate Against a Key Driver of Huntington’s Disease Progression in a Matter of Weeks
PALO ALTO, Calif. & MENLO PARK, Calif.--(BUSINESS WIRE)--Oct 7, 2026-- Industry benchmarks place the path from hit identification to candidate nomination at approximately 12-18 months. Working together, Transcripta Bio and Synfini…
Why a Huntington's patient isn't fazed by the waning effect of UniQure's gene therapy
Lauren Holder is an advocate for the Huntington’s disease community who is also living with the early stages of the progressive and fatal neurodegenerative condition. I called her Tuesday to get her reaction to UniQure’s gene therapy…
uniQure Plunges on Additional Data From Huntington's Disease Study
QURE Quick QuoteQURE ACIU Quick QuoteACIU PGEN Quick QuotePGEN uniQure (QURE Quick QuoteQURE - Free Report) announced mixed additional data from the ongoing phase I/II studies on investigational gene therapy, ifezuntirgene inilparvovec,…
uniQure: A Speculative Buy After Huntington's Disease Trial's 4-Year Data Update
Seeking Alpha Md Saiful Islam Khan/iStock via Getty Images On Tuesday, Sep. 29, uniQure N.V. (QURE) announced their highly anticipated, four-year data from their ongoing p1/2 trial studying AMT-130, a gene therapy candidate, for…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
pluang.com4
-
seekingalpha.com4
-
accessnewswire.com2
-
247wallst.com1
-
biopharmadive.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 35 articles, not a forecast.